Molika Ashford

The company is seeing continuing growth for its existing clinical products as it moves resources toward commercialization of its Guardant Shield CRC screening test.

The company discussed what it believes are compelling new results on the impact of its testing on patient outcomes during a call discussing its Q1 earnings.

The New Zealand-based diagnostics firm is hoping the coming year will be a tipping point toward new guideline inclusion and broader adoption.

Physicians are beginning to face patient questions about commercially available tests without definitive utility data to guide them.

At AACR, the company highlighted new prospective and retrospective data that it believes helps set its platform apart from other available ctDNA technologies.

Data from an early-phase trial has spurred the firm to validate its blood-based residual disease assay, Radar, in neoadjuvant bladder cancer.

The company has derived and validated a mutational and gene expression score that predicts immunotherapy benefit across tumor types.

The data, from a large prospective cohort, support the value of chemotherapy for ctDNA-positive patients, regardless of clinical stage.

The company believes the new results, from an initial prospective multisite trial, reflect what it can achieve in the larger cohort that it is now planning to recruit.

The company said it hasn't changed its plans to submit its Shield test to the FDA, but the lower-than-expected performance data led to a significant drop in Guardant's share price.